Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Petosemtamab + Pembrolizumab in 1L R/M PD-L1+ HNSCC
NCT06525220Phase 3Active, not recruiting
- Sponsor
- Genmab
- Start
- Sep 2024
- Primary completion
- Jan 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial of petosemtamab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Genmab. Primary endpoints: Overall Survival at 3 years and Objective Response Rate at 2 years. Started Sep 2024; status: active, not recruiting.
02
Drugs
petosemtamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06525220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525220.